Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women

Results from the women's health initiative

Zhihong Gong, Aaron K. Aragaki, Rowan T. Chlebowski, Joann E. Manson, Thomas E. Rohan, Chu Chen, Mara Z. Vitolins, Lesley F. Tinker, Erin S. Leblanc, Lewis H. Kuller, Lifang Hou, Michael J. Lamonte, Juhua Luo, Jean Wactawski-Wende

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women's Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p <0.001) and of several site-specific cancers (HR, 1.2-1.4, and up to over twofold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p <0.001). There was no overall difference in cancer incidence by diabetes therapy (p = 0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 vs. 1.45; p = 0.007) and for breast cancer (HRs, 0.50 vs. 1.29; p = 0.05). Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long-term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti-diabetes medications. Future studies are needed to determine the long-term effect of metformin in cancer risk and survival from cancer.

Original languageEnglish (US)
Pages (from-to)1915-1927
Number of pages13
JournalInternational Journal of Cancer
Volume138
Issue number8
DOIs
StatePublished - Apr 15 2016

Fingerprint

Metformin
Women's Health
Incidence
Neoplasms
Proportional Hazards Models

Keywords

  • diabetes
  • incidence
  • invasive cancer
  • metformin
  • mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women : Results from the women's health initiative. / Gong, Zhihong; Aragaki, Aaron K.; Chlebowski, Rowan T.; Manson, Joann E.; Rohan, Thomas E.; Chen, Chu; Vitolins, Mara Z.; Tinker, Lesley F.; Leblanc, Erin S.; Kuller, Lewis H.; Hou, Lifang; Lamonte, Michael J.; Luo, Juhua; Wactawski-Wende, Jean.

In: International Journal of Cancer, Vol. 138, No. 8, 15.04.2016, p. 1915-1927.

Research output: Contribution to journalArticle

Gong, Z, Aragaki, AK, Chlebowski, RT, Manson, JE, Rohan, TE, Chen, C, Vitolins, MZ, Tinker, LF, Leblanc, ES, Kuller, LH, Hou, L, Lamonte, MJ, Luo, J & Wactawski-Wende, J 2016, 'Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative', International Journal of Cancer, vol. 138, no. 8, pp. 1915-1927. https://doi.org/10.1002/ijc.29944
Gong, Zhihong ; Aragaki, Aaron K. ; Chlebowski, Rowan T. ; Manson, Joann E. ; Rohan, Thomas E. ; Chen, Chu ; Vitolins, Mara Z. ; Tinker, Lesley F. ; Leblanc, Erin S. ; Kuller, Lewis H. ; Hou, Lifang ; Lamonte, Michael J. ; Luo, Juhua ; Wactawski-Wende, Jean. / Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women : Results from the women's health initiative. In: International Journal of Cancer. 2016 ; Vol. 138, No. 8. pp. 1915-1927.
@article{0fe21c8fbad54b3790e460bc9b8004c8,
title = "Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative",
abstract = "Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women's Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use. Cox regression models were used to estimate hazard ratios (HR) and their 95{\%} confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p <0.001) and of several site-specific cancers (HR, 1.2-1.4, and up to over twofold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p <0.001). There was no overall difference in cancer incidence by diabetes therapy (p = 0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 vs. 1.45; p = 0.007) and for breast cancer (HRs, 0.50 vs. 1.29; p = 0.05). Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long-term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti-diabetes medications. Future studies are needed to determine the long-term effect of metformin in cancer risk and survival from cancer.",
keywords = "diabetes, incidence, invasive cancer, metformin, mortality",
author = "Zhihong Gong and Aragaki, {Aaron K.} and Chlebowski, {Rowan T.} and Manson, {Joann E.} and Rohan, {Thomas E.} and Chu Chen and Vitolins, {Mara Z.} and Tinker, {Lesley F.} and Leblanc, {Erin S.} and Kuller, {Lewis H.} and Lifang Hou and Lamonte, {Michael J.} and Juhua Luo and Jean Wactawski-Wende",
year = "2016",
month = "4",
day = "15",
doi = "10.1002/ijc.29944",
language = "English (US)",
volume = "138",
pages = "1915--1927",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women

T2 - Results from the women's health initiative

AU - Gong, Zhihong

AU - Aragaki, Aaron K.

AU - Chlebowski, Rowan T.

AU - Manson, Joann E.

AU - Rohan, Thomas E.

AU - Chen, Chu

AU - Vitolins, Mara Z.

AU - Tinker, Lesley F.

AU - Leblanc, Erin S.

AU - Kuller, Lewis H.

AU - Hou, Lifang

AU - Lamonte, Michael J.

AU - Luo, Juhua

AU - Wactawski-Wende, Jean

PY - 2016/4/15

Y1 - 2016/4/15

N2 - Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women's Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p <0.001) and of several site-specific cancers (HR, 1.2-1.4, and up to over twofold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p <0.001). There was no overall difference in cancer incidence by diabetes therapy (p = 0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 vs. 1.45; p = 0.007) and for breast cancer (HRs, 0.50 vs. 1.29; p = 0.05). Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long-term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti-diabetes medications. Future studies are needed to determine the long-term effect of metformin in cancer risk and survival from cancer.

AB - Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women's Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p <0.001) and of several site-specific cancers (HR, 1.2-1.4, and up to over twofold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p <0.001). There was no overall difference in cancer incidence by diabetes therapy (p = 0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 vs. 1.45; p = 0.007) and for breast cancer (HRs, 0.50 vs. 1.29; p = 0.05). Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long-term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti-diabetes medications. Future studies are needed to determine the long-term effect of metformin in cancer risk and survival from cancer.

KW - diabetes

KW - incidence

KW - invasive cancer

KW - metformin

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84958889686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958889686&partnerID=8YFLogxK

U2 - 10.1002/ijc.29944

DO - 10.1002/ijc.29944

M3 - Article

VL - 138

SP - 1915

EP - 1927

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -